Showing results (11-20 of 15) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
JAMA|February 24, 2025
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical TrialXiaotian Zhang, Jufeng Wang, Gang Wang, et al.Cancer Immunology, Immunotherapy : CII|January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trialJifang Gong, Junning Cao, Qingyuan Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II StudyHuiqiang Huang, Rong Tao, Siguo Hao, et al.Nature Medicine|February 1, 2024
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 studyJin Li, Zhendong Chen, Yuxian Bai, et al.The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.Pageof 2